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Sequential Findings From the TVT Registry*Michael J. Reardon, MD,y Neal S. Kleiman, MDzSEE PAGE 2813T ranscatheter aortic valve replacement (TAVR)has rapidly expanded in the United Statesand worldwide. The approval of the ﬁrst 2
TAVR prostheses in the United States is based on
data from randomized trials showing survival rates
superior to conservative medical therapy in nonoper-
able patients (1,2) and comparable or superior to surgi-
cal aortic valve replacement (SAVR) for patients at
high surgical risk (3,4). Data from these trials have
now been extended to 5-year outcomes for the
PARTNER (Placement of Aortic Transcatheter Valves)
trial and 2-year outcomes for the CoreValve trial,
and continue to conﬁrm the initial ﬁndings (5–8).
These trials represent some of the most robust clinical
investigations available in the ﬁeld of valvular heart
disease. However, it has long been recognized that
observations from clinical trials are not necessarily
reﬂective of outcomes and practices in the broader
population, often referred to as “the real world” (9).
The TVT (Transcatheter Valve Therapies) Registry
was created to address this concern. It arose from a
close collaboration between the U.S. Center for
Medicare & Medicaid Services (CMS), the American
College of Cardiology, and the Society of Thoracic
Surgeons (STS). Speciﬁcally, the goal of the TVT
Registry was to provide a data repository and
reporting structure independent from industry to
monitor the safety and effectiveness of approved*Editorials published in the Journal of the American College of Cardiology
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and The Annals of Thoracic Surgery.TAVR devices (10). The majority of patients receiving
TAVR are covered by Medicare, and enrollment in the
registry is mandatory for physicians and institutions
to receive payment for TAVR from CMS. It is thus
anticipated that the registry will capture nearly all
commercially funded cases of TAVR and will involve
every U.S. physician implanting transcatheter
valves, including the authors. The initial in-hospital
outcomes of the TVT Registry were reported by
Mack et al. (11) in 2013 and the 1-year outcomes by
Holmes et al. (12).In this issue of the Journal, Holmes et al. (13) pro-
vide further updates of the TVT Registry. The pre-
dominant theme of the current report is that the ﬁeld
of TAVR is exceptionally dynamic. The report cap-
tures a total of 26,414 TAVR procedures from 348
centers in 48 states between 2012 and December 31,
2014, and thus allows comparison of the ﬁrst 3 years
of commercial TAVR implantation. During this time-
frame, we have seen a dramatic surge in the number
of centers implanting transcatheter valves (the num-
ber of participating sites more than doubled between
2012 and 2014), as well as U.S. Food and Drug
Administration approval of new devices and CMS
approval of new access routes. Patient outcomes
remain extremely encouraging: the procedural suc-
cess of device implantation in the proper position is
excellent at 97.4%, with 95% of these having a mean
residual gradient <20 mm Hg; mortality (4.4%),
myocardial infarction (0.4%), renal injury stage 3
(2.2%), and stroke (2.2%) are low; and conversion to
open surgery remains highly unusual at 1.3%.
Equally important, the report provides insight into
how the procedure is evolving. Patient characteristics
seem to suggest a rightward shift in the selection of
patients for TAVR, such that fewer extremely high-risk
and more intermediate- to high-risk patients are
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2825undergoing the procedure. There are subtle but sig-
niﬁcant decrements in patient age and baseline risk.
The median age decreased from 84 to 83 years, and the
median STS predicted risk of mortality among enrolled
patients fell from 7.05% to 6.69%, accompanied by a
small decrement in the proportion of patients with STS
risk scores $15%. Only about 1 in 5 patients had risk
scores <4%. Noncardiac morbidities, such as the pro-
portion on home oxygen, tended to decrease as did
measures of frailty. Thus, although not completely
alleviating early concern about “creep” of the proce-
dure into inappropriately low-risk patient pop-
ulations, this study shows that the patients remain
elderly and at high risk, and are symptomatic and frail.
These observations suggest that patient selection for
TAVR in the United States has remained reasonable,
with excellent efﬁcacy and continued safety.
The observations concerning procedure perfor-
mance are particularly interesting. Although it is
difﬁcult within the registry to distinguish between
overall trends and more conservative practices
by physicians new to TAVR and to the registry,
several observations are apparent. Over time, TAVR
implanters have become more adept at integrating
computed tomography angiogram data (used to
assess the aortic annulus in 27.9% in the ﬁrst cohort
vs. 51.9% in the second cohort). Notably, the propor-
tion of patients receiving moderate sedation rather
than general anesthesia rose from 1.6% to 5.1% and
the proportion of percutaneous TAVR rose from 21.1%
to 40.8%, whereas the proportion of transapical and
other nonfemoral access use declined.
As TAVR enters the mainstream of clinical practice,
the registry must embrace new challenges, but will
also be able to provide new opportunities. First, only
the ﬁrst 3 years of TAVR are currently included in the
registry. Although 5-year results from the PARTNER
trial show no indication of structural valve degener-
ation, surgical experience has shown that in many
cases, structural valve degeneration can become
apparent fairly abruptly after this period. Second, the
recent National Coverage Decision by CMS speciﬁesthe requisite operator and institutional requirements,
particularly with respect to open surgical volume, to
develop a TAVR program. Paradoxically, if the current
trials of TAVR in patients at intermediate risk for SAVR,
such as SURTAVI (Surgical Replacement and Trans-
catheter Aortic Valve Implantation) (NCT01586910)
andPARTNER II (NCT01314313), demonstrate adequate
long-term outcomes for these lower-risk patients
following TAVR, the number of SAVRs will drop and
meeting the current CMS requirements will become
more difﬁcult. Accordingly, the registry will become
more useful in elucidating the relationship among
operator experience, institutional volume, and the
likelihood of achieving satisfactory clinical outcomes.
The TVT Registry also can be used with other
national registries such as the U.K. Registry (14),
GARY (German Aortic Valve Registry) (15), and France
II Registry (16) to achieve very high-volume data for
unusual occurrences with TAVR.
Finally, the TVT Registry offers another unique set
of opportunities. TVT played an important role in the
acceptance and CMS approval of direct aortic access
for TAVR. In Sweden, the TASTE (Thrombus Aspira-
tion in ST-Elevation Myocardial Infarction in Scandi-
navia) investigators demonstrated that simple clinical
questions concerning currently available therapy,
such as intracoronary thrombectomy during primary
percutaneous coronary intervention, can be answered
using a randomized trial with data collection per-
formed using an existing registry (SCAAR [Swedish
Coronary Angiography and Angioplasty Registry])
(17). Important questions remain to be resolved,
particularly in regard to antithrombotic therapies, in
patients who have undergone TAVR. The registry is
likely to become a useful mechanism to resolve these
questions in a broad national population.
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